<DOC>
	<DOCNO>NCT00078533</DOCNO>
	<brief_summary>Patients type blood cell cancer , blood disease genetic disease receive stem cell transplant . The donor stem cell either brother sister another relative closely match unrelated donor . We ask patient participate study test blood cell donor grown special way , prevent patient get infection virus call Cytomegalovirus CMV . CMV virus cause serious infection patient suppress immune system . It usually affect lung cause serious pneumonia , also affect intestinal tract , liver eye . Approximately 2/3 normal people harbor virus body . In healthy people CMV rarely cause problem immune system keep control . If patient and/or donor positive CMV , risk develop CMV disease patient immune system weak post transplant . Usually , risk high first 3-4 month transplant . CMV disease prevent time people use drug kill virus Ganciclovir , Foscarnet , Cidofovir . However , medication many side effect give daily vein approximately 4-5 month transplant . One side effect take new immune system much longer develop effective defense virus . Therefore , medicine stop , patient still chance develop CMV disease . We want see use kind white blood cell call T cell grown stem cell donor instead regular treatment Ganciclovir Foscarnet prevent CMV `` flaring '' . These cell train attack CMV virus infect cell . We grow T cell blood take donor patient transplant . These cell call CMV-specific cytotoxic T-lymphocytes CMV CTL , give patient around 30 day transplant . We use sort therapy treat different virus cause problem transplant call Epstein Barr Virus ( EBV ) . Doctors place use similar T cell treat prevent CMV infection transplant see significant problem . These CMV specific cytotoxic T cell investigational product approve Food Drug Administration .</brief_summary>
	<brief_title>Cytotoxic T-Lymphocytes Prophylaxis Cytomegalovirus After Allogeneic Stem Cell Transplant</brief_title>
	<detailed_description>If patient donor eligible , take 100-120 ml ( 20-24 teaspoonful ) blood donor 3-4 week transplant . We take much blood safe patient donor . We use blood grow T cell . We first infect peripheral blood mononuclear cell specially produce human virus adenovirus ) carry part CMV gene monocyte stimulate T cell . This stimulation train T cell kill cell pp65 CMV virus surface . If approach insufficient stimulate T cell kill pp65 CMV virus grow special type cell call dendritic cell stimulate T cell put specially produce human virus ( adenovirus ) carry part CMV gene ( call pp65 ) dendritic cell . These dendritic cell treat radiation grow . They use stimulate T cell . This stimulation train T cell kill cell pp65 CMV virus surface . We grow CMV specific CTLs stimulation EBV infect cell ( make blood donor infect EBV laboratory ) . We also put adenovirus carry CMV pp65 gene EBV infect cell CMVpp65 . These EBV infect cell treat radiation grow . Once make sufficient number T cell test make sure kill cell CMVpp65 surface . To make sure cell wo n't attack patient tissue , test cell lymphoblasts grow laboratory . These use check CMV CTL attack . Alternatively , could take small piece skin patient grow skin cell also use check CMV CTL attack . The skin biopsy do time another procedure bone marrow . The donor 's CMV CTL cell thaw injected patient intravenous line period 10 minute patient receive Benadryl Tylenol . The patient receive dose CMV CTL cell day 30 follow transplant agree well enough . We give antiviral medication study monitor CMV level weekly least 30 day transplant . If initial dose CMV CTL cell patient develop viral infection , may eligible receive one additional injection CTLs dose first injection . If CMV level blood continue rise dose T cell patient receive treatment Ganciclovir , Foscarnet , Cidofuvir . The patient continue follow BMT clinic injection . They see clinic , hospital contact research nurse blood test ( monitor blood count , kidney liver function monitor virus ) weekly first 60 day CTL infusion , 3 , 6 , 9 12 month . To learn way T cell work body , extra 20-40 ml ( 4-8 teaspoon ) blood take infusion 24 hour infusion ( optional depending patient preference ) , 1 , 2 , 4 6 week infusion . After , blood take every 3 month 1 year . The amount blood take first 12 month 260-460mls ( 1-2 cup ) . Total time participation study 1 year .</detailed_description>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<criteria>Inclusion criterion : Recipients allogeneic donor stem cell transplant risk CMV reactivation CMV seropositive stem cell donor least 30 day post transplant . Recipients early evidence CMV reactivation great 2 leukocyte less 10 leukocyte positive CMV Ag per 100,000 cell . No evidence graftversushost disease ( GVHD ) &gt; Grade II time enrollment . Life expectancy &gt; 30 day No severe intercurrent infection Lansky/Karnofsky score great equal 60 Absence severe renal disease ( Creatinine &gt; x 3 normal age ) Absence severe hepatic disease ( direct bilirubin &gt; 3 mg/dl SGOT &gt; 500 ) Not receive Ganciclovir , Foscarnet , Cidofovir antiviral therapy CMV reactivation Patient/guardian able give inform consent Patients CMV negative stem cell donor Patients GVHD Grades IIIIV Patients receive antiviral therapy CMV reactivation viral infection adenovirus herpes virus Patients significant CMV reactivation . Significant CMV reactivation define one CMV Antigenemia read &gt; 10 leukocyte positive CMV Ag per 100,000 cell Patients less 50 % donor chimerism either peripheral blood bone marrow patient relapse original disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Allogeneic</keyword>
	<keyword>Transplant</keyword>
	<keyword>CMV</keyword>
	<keyword>Stem Cell</keyword>
	<keyword>Donor</keyword>
	<keyword>Allogeneic stem cell recipient risk CMV reactivation</keyword>
</DOC>